Pro Pharmaceutical (000739.SZ): Ketone theobromine sustained-release tablets have obtained a drug registration certificate.

Zhitong Finance APP reported that Pro Pharmaceuticals (000739.SZ) announced that its holding subsidiary, Zhejiang Prokangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical"), has received the "Drug Registration Certificate" for Ketone Cocoa Alkaloid Sustained Release Tablets issued by the National Medical Products Administration. Ketone Cocoa Alkaloid Sustained Release Tablets are peripheral vasodilators used for peripheral vascular diseases, including intermittent claudication and rest pain. According to relevant data, the domestic market size for Ketone Cocoa Alkaloid Sustained Release Tablets is expected to reach approximately 52.27 million tablets in 2025, with a sales amount of around 262 million yuan.